logo
Plus   Neg
Share
Email

Actuant Executives Adopt 10b5-1 Plans - Quick Facts

Actuant Corp. (ATU) announced that certain of its executives have adopted prearranged trading plans in accordance with guidelines specified by Rule 10b5-1 under the Securities Exchange Act of 1934 and the Company's policies with respect to insider sales.

As per the 10b5-1 plans, the executives (Arzbaecher, Goldstein, Kobylinski, Lampereur) will be exercising stock options and immediately selling the shares of Actuant stock because the underlying options are approaching the end of their 10 year term. In addition, Arzbaecher and Boel plan to sell certain shares held outright. The transactions may take place from time-to-time on or after April 5, 2012, subject to certain 10b5-1 plan criteria, including certain minimum price levels and daily volume activity.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT